Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Eugenio Andraca‐Carrera
Observed name:
Eugenio Andraca-Carrera
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
OpenAlex ID:
A5083380171
No Association of Abacavir Use With Myocardial Infarction
2012
·
Xiao Ding
, Eugenio Andraca-Carrera
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
180
Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial
2020
·
John Sharretts
, Ovidiu Galescu
, et al.
·
New England Journal of Medicine
·
166
Inhaled Corticosteroids and LABAs — Removal of the FDA’s Boxed Warning
2018
·
Sally M. Seymour
, Robert Lim
, et al.
·
New England Journal of Medicine
·
26
PDF
Assessing the Safety of Glucose-Lowering Drugs — A New Focus for the FDA
2020
·
William H. Chong
, Lisa B. Yanoff
, et al.
·
New England Journal of Medicine
·
22
Statement on P-values
2021
·
Thomas Gwise
, Mark D. Rothmann
, et al.
·
Statistics in Biopharmaceutical Research
·
6
PDF
A structured framework for adaptively incorporating external evidence in sequentially monitored clinical trials
2022
·
Evan Kwiatkowski
, Eugenio Andraca-Carrera
, et al.
·
Journal of Biopharmaceutical Statistics
·
3
Underscoring the Importance of Allopurinol in Treating Gout: Results of a Food and Drug Administration–Mandated Safety Trial
2020
·
Nikolay P. Nikolov
, Sally Seymour
, et al.
·
Arthritis & Rheumatology
·
2
Show more works
View as search
Works count:
7
Citation count:
405
H-index:
5
I10-index:
4
Year
Topic
Type